Insider Buying: Kindred Biosciences Director Buys 47,000 Shares of Stock (KIN)
Kindred Biosciences (NYSE:KIN) Director Oleg Nodelman acquired 47,000 shares of Kindred Biosciences stock on the open market in a transaction dated Thursday, August 28th. The shares were purchased at an average price of $10.85 per share, with a total value of $509,950.00. Following the acquisition, the director now directly owns 50,000 shares in the company, valued at approximately $542,500. The purchase was disclosed in a document filed with the SEC, which is available at this link.
KIN has been the subject of a number of recent research reports. Analysts at BMO Capital Markets cut their price target on shares of Kindred Biosciences from $30.00 to $19.00 in a research note on Thursday, August 21st. Separately, analysts at Leerink Swann cut their price target on shares of Kindred Biosciences from $29.00 to $11.25 in a research note on Thursday, August 21st. Finally, analysts at Roth Capital cut their price target on shares of Kindred Biosciences to $11.50 in a research note on Thursday, August 21st. Two equities research analysts have rated the stock with a buy rating, Kindred Biosciences presently has a consensus rating of “Buy” and an average price target of $13.92.
Shares of Kindred Biosciences (NYSE:KIN) traded down 0.55% on Friday, hitting $10.91. The stock had a trading volume of 73,220 shares. Kindred Biosciences has a 52-week low of $8.75 and a 52-week high of $26.99. The stock’s 50-day moving average is $14.74 and its 200-day moving average is $17.82. The company’s market cap is $215.0 million.
Kindred Biosciences (NYSE:KIN) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.42) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.35) by $0.07. Analysts expect that Kindred Biosciences will post $-1.75 EPS for the current fiscal year.
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.